Volume | 848,713 |
|
|||||
News | - | ||||||
Day High | 79.76 | Low High |
|||||
Day Low | 79.02 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alcon Inc | ALC | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
79.42 | 79.02 | 79.76 | 78.47 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,914 | 848,713 | $ 79.43 | $ 67,411,397 | - | 69.44 - 88.2312 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:19:49 | 1 | $ 79.40 | USD |
Alcon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
39.59B | 499.70M | - | 9.46B | 974M | 1.95 | 40.65 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alcon News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 82.00 | 82.47 | 78.28 | 79.85 | 906,217 | -2.59 | -3.16% |
1 Month | 83.83 | 84.96 | 78.28 | 82.23 | 813,054 | -4.42 | -5.27% |
3 Months | 77.18 | 88.2312 | 74.30 | 81.87 | 920,043 | 2.23 | 2.89% |
6 Months | 73.19 | 88.2312 | 69.44 | 78.01 | 874,244 | 6.22 | 8.50% |
1 Year | 69.95 | 88.2312 | 69.44 | 78.57 | 822,447 | 9.46 | 13.52% |
3 Years | 74.19 | 88.78 | 55.21 | 74.20 | 856,748 | 5.22 | 7.04% |
5 Years | 54.46 | 88.78 | 39.37 | 67.23 | 982,188 | 24.95 | 45.81% |
Alcon Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |